JRCT ID: jRCT2080221000
Registered date:10/02/2010
Basic Information
Recruitment status | |
---|---|
Health condition(s) or Problem(s) studied | Type 2 Diabetes Mellitus |
Date of first enrollment | 10/02/2010 |
Target sample size | |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : Dapagliflozin INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : 10mg, oral, once daily |
Outcome(s)
Primary Outcome | |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | - Already on voglibose treatment with a steady dosage for at least 8 weeks - Provision of informed consent prior to any study specific procedures - Diagnosed with type 2 diabetes |
Exclude criteria | - Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease. - The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history. |
Related Information
Primary Sponsor | AstraZeneca |
---|---|
Secondary Sponsor | Bristol-Myers Squibb |
Source(s) of Monetary Support | |
Secondary ID(s) | JapicCTI-101033 |
Contact
Public contact | |
Name | |
Address | RD-clinical-information-Japan@astrazeneca.com |
Telephone | |
Affiliation | AstraZeneca KK |
Scientific contact | |
Name | |
Address | |
Telephone | |
Affiliation |